Login Register Cart 0
Generic placeholder image

Current Bioinformatics

Editor-in-Chief

ISSN (Print): 1574-8936
ISSN (Online): 2212-392X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Identification of Key mRNAs and lncRNAs Associated with the Effects of Anti-TWEAK on Osteosarcoma

Author(s): Mingxuan Yang, Liangtao Zhao, Xuchang Hu, Haijun Feng and Xuewen Kang*

Volume 16, Issue 1, 2021

Published on: 26 June, 2020

Page: [154 - 161] Pages: 8

DOI: 10.2174/1574893615999200626191405

Price: $65

Abstract

Background: Osteosarcoma (OS) is one of the most common primary malignant bone tumors in teenagers. Emerging studies demonstrated TWEAK and Fn14 were involved in regulating cancer cell differentiation, proliferation, apoptosis, migration and invasion.

Objective: The present study identified differently expressed mRNAs and lncRNAs after anti- TWEAK treatment in OS cells using GSE41828.

Methods: We identified 922 up-regulated mRNAs, 863 down-regulated mRNAs, 29 up-regulated lncRNAs, and 58 down-regulated lncRNAs after anti-TWEAK treatment in OS cells. By constructing PPI networks, we identified several key proteins involved in anti-TWEAK treatment in OS cells, including MYC, IL6, CD44, ITGAM, STAT1, CCL5, FN1, PTEN, SPP1, TOP2A, and NCAM1. By constructing lncRNAs co-expression networks, we identified several key lncRNAs, including LINC00623, LINC00944, PSMB8-AS1, LOC101929787.

Result: Bioinformatics analysis revealed DEGs after anti-TWEAK treatment in OS were involved in regulating type I interferon signaling pathway, immune response-related pathways, telomere organization, chromatin silencing at rDNA, and DNA replication. Bioinformatics analysis revealed differently expressed lncRNAs after anti-TWEAK treatment in OS were related to telomere organization, protein heterotetramerization, DNA replication, response to hypoxia, TNF signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Apoptosis, NF-kappa B signaling pathway, MAPK signaling pathway, FoxO signaling pathway.

Conclusion: This study provided useful information for understanding the mechanisms of TWEAK underlying OS progression and identifying novel therapeutic markers for OS.

Keywords: Long non-coding RNA, TWEAK, expression profiling, protein-protein interaction analysis, co-expression analysis, osteosarcoma

« Previous Next »
Graphical Abstract

[1]
Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003; 14(3-4): 241-9.
[http://dx.doi.org/10.1016/S1359-6101(03)00019-4] [PMID: 12787562]
[2]
Yin J, Liu YN, Tillman H, et al. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Res 2014; 74(16): 4306-17.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-3233] [PMID: 24970477]
[3]
Yin X, Luistro L, Zhong H, et al. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response. Clin Cancer Res 2013; 19(20): 5686-98.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-0405] [PMID: 23974006]
[4]
Fletcher CD, Mertens F, Unni K. World Health Organization classification of tumours: pathology and genetics tumours of soft tissue and bone. IARC Publications 2002.
[5]
Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH, Wang WJ. MicroRNAs in osteosarcoma. Clin Chim Acta 2015; 444: 9-17.
[http://dx.doi.org/10.1016/j.cca.2015.01.025] [PMID: 25661090]
[6]
Yu H, Sun H, Bai Y, et al. MEF2D overexpression contributes to the progression of osteosarcoma. Gene 2015; 563(2): 130-5.
[http://dx.doi.org/10.1016/j.gene.2015.03.046] [PMID: 25814384]
[7]
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26(1): 139-40.
[http://dx.doi.org/10.1093/bioinformatics/btp616] [PMID: 19910308]
[8]
Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41(Database issue): D808-15.
[PMID: 23203871]
[9]
Dong B, Wang G, Yao J, et al. Predicting novel genes and pathways associated with osteosarcoma by using bioinformatics analysis. Gene 2017; 628: 32-7.
[http://dx.doi.org/10.1016/j.gene.2017.06.058] [PMID: 28687333]
[10]
Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer Res 2009; 69(23): 8839-43.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-1970] [PMID: 19934336]
[11]
Qureshi A, et al. Osteosarcoma arising on a background of Paget's disease report of an unusual case Case Reports 2013.
[http://dx.doi.org/10.1136/bcr-2012-007770]
[12]
Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002; 39(3): 372-8.
[http://dx.doi.org/10.1354/vp.39-3-372] [PMID: 12014501]
[13]
Li W, Xie P, Ruan WH. Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis. J Bone Oncol 2016; 5(2): 80-5.
[http://dx.doi.org/10.1016/j.jbo.2016.05.003] [PMID: 27335776]
[14]
Gao L, Cheng XL, Cao H. LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. Biochimie 2018; 152: 63-72.
[http://dx.doi.org/10.1016/j.biochi.2018.06.015] [PMID: 29959065]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy